Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas' and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
解鎖市場時間軸與訊號動態
此公司進入各市場的次序 — 由最舊至最新
Royalty Pharma任命孫鍶銘為亞洲區主管
Royalty Pharma任命孫鍶銘為亞洲區主管
註冊以查看完整訊號動態
Royalty Pharma 的國際擴張與競爭對手的比較
Royalty Pharma你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Royalty Pharma你 | 0 | 0 | 0% | 0 | 11 |
目前並無招聘
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
Royalty Pharma任命孫健為亞洲區高級副總裁兼主管，自2026年5月起生效，以擴展其全球平台。
Royalty Pharma任命孫鍶銘為高級副總裁兼亞洲區主管，自2026年5月起生效，將常駐香港領導公司在亞洲的特許權業務。
Royalty Pharma任命孫鍶銘為高級副總裁兼亞洲區主管，自2026年5月起生效，將常駐香港領導亞洲特許權業務。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Royalty Pharma 業務、市場及增長訊號的快速解答。
